Last $161.98 USD
Change Today +2.07 / 1.29%
Volume 1.1M
SHPG On Other Exchanges
Symbol
Exchange
SHPG is not on other exchanges.
As of 12:47 PM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

5 Riverwalk

Citywest Business Campus

Dublin, 24

Ireland

Phone: 353 1 429 7700

Fax:

Shire plc, together with its subsidiaries, operates as a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Strategy The company’s strategy for achieving its vision is to focus on treatments and services for symptomatic conditions in areas of high medical need, so patients experience a noticeable and ongoing improvement in their lives. Through deep understanding of patients’ needs, the company develops and provides healthcare in the areas of behavioral health and gastro intestinal conditions; rare genetic diseases; regenerative medicine; and other symptomatic conditions treated by specialist physicians. Business Units The company operates in three distinct business units: Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT), and Regenerative Medicine (RM). SP Treatments for Attention Deficit and Hyperactivity Disorder (ADHD) VYVANSE/VENVANSE/ELVANSE/TYVENSE: VYVANSE is the pro-drug stimulant for the treatment of ADHD, where the amino acid l-lysine is linked to d-amphetamine. VYVANSE is therapeutically inactive until metabolized in the body. VYVANSE is available in the U.S. in 6 dosage strengths: 20mg, 30mg, 40mg, 50mg, 60mg, and 70mg. VYVANSE had New Chemical Entity (NCE) exclusivity through to February 23, 2012 and is also covered by U.S. patents of which the last to expire remain in effect until June 29, 2023. VYVANSE was approved by Health Canada for the treatment of ADHD in paediatric patients aged 6 to 12 in 2009, for adolescents and adults in 2010, and was launched in Canada in 2011. VENVANSE was granted marketing authorization by ANVISA, the Brazilian health authority, for the treatment of ADHD in children aged 6-12, and launched in 2011. ELVANSE is indicated as part of a comprehensive treatment program for ADHD in children aged 6 years of age and over when response to previous methylphenidate treatment is considered clinically inadequate. ADDERALL XR ADDERALL XR is an extended release treatment for ADHD, which uses MICROTROL drug delivery technology and is designed to provide once-daily dosing. It is available in 5mg, 10mg, 15mg, 20mg, 25mg and 30mg capsules. The U.S. Food and Drug Administration (FDA) approved ADDERALL XR as a once-daily treatment for children aged 6 to 12 with ADHD in 2001, for adults in 2004 and for adolescents aged 13 to 17 in 2005. Teva Pharmaceutical Industries, Ltd. and Impax Laboratories, Inc. (Impax) commenced commercial shipment of their authorized generic versions of ADDERALL XR in 2009. Shire receives royalties from Impax’s sales of authorized generic ADDERALL XR. INTUNIV INTUNIV is the first in a new class of approved ADHD medications, a selective alpha-2A receptor agonist indicated for the treatment of ADHD. Alpha-2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signalling in the prefrontal cortex. INTUNIV is non-scheduled and has no known potential for abuse or dependence. The FDA approved INTUNIV as a once-daily monotherapy treatment of ADHD in children and adolescents aged 6 to 17 and as adjunctive therapy to stimulants in 2011. It is available in 1mg, 2 mg, 3 mg and 4 mg tablets. EQUASYM In March 2009, Shire acquired from UCB the worldwide rights (excluding the U.S., Canada and Barbados) to EQUASYM immediate release and modified release (XL) preparations for the treatment of ADHD in children and adolescents aged 6 to 17. Shire is focusing exclusively on the XL form. As of December 31, 2012 EQUASYM XL was commercially available in 10 countries in 10mg, 20mg and 30mg strengths. EQUASYM XL is marketed in Mexico and South Korea under the trade name METADATE CD. Treatments for gastrointestinal (GI) diseases - Ulcerative Colitis (UC) LIALDA/MEZAVANT LIALDA is indicated in the U.S. and Canada for the induction of remission in patients with mild to moderately active UC and for the maintenance of remission of UC. LIALDA is the FDA-approved once-daily oral formulation of mesalamine indicated for the induction and maintenance of remission. LIALDA contains the commercially available mesalamine dose per tablet (1.2g), so patients can take

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SHPG:US $161.98 USD +2.07

SHPG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $204.35 USD -1.32
CSL Ltd A$68.01 AUD +0.03
Forest Laboratories Inc $91.96 USD -0.17
UCB SA €59.67 EUR +0.13
Valeant Pharmaceuticals International Inc C$146.93 CAD -2.45
View Industry Companies
 

Industry Analysis

SHPG

Industry Average

Valuation SHPG Industry Range
Price/Earnings 22.0x
Price/Sales 6.0x
Price/Book 5.5x
Price/Cash Flow 46.9x
TEV/Sales 6.3x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHIRE PLC-ADR, please visit www.shire.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.